Health Catalyst (NASDAQ:HCAT – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
85.0% of Health Catalyst shares are owned by institutional investors. 2.6% of Health Catalyst shares are owned by company insiders. Comparatively, 1.7% of MDxHealth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations and price targets for Health Catalyst and MDxHealth, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Health Catalyst | 1 | 7 | 5 | 0 | 2.31 |
| MDxHealth | 1 | 0 | 4 | 0 | 2.60 |
Risk & Volatility
Health Catalyst has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.
Profitability
This table compares Health Catalyst and MDxHealth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Health Catalyst | -57.20% | -4.30% | -2.16% |
| MDxHealth | -31.07% | -1,078.01% | -21.71% |
Valuation & Earnings
This table compares Health Catalyst and MDxHealth”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Health Catalyst | $311.14 million | 0.29 | -$177.97 million | ($2.54) | -0.48 |
| MDxHealth | $107.88 million | 1.55 | -$33.52 million | ($0.67) | -5.03 |
MDxHealth has lower revenue, but higher earnings than Health Catalyst. MDxHealth is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.
Summary
Health Catalyst beats MDxHealth on 9 of the 14 factors compared between the two stocks.
About Health Catalyst
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
About MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
